The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer

Gynecologic Oncology

Volumn 134, Issue 3, 2014, Pages 462-467

  Rosen, Barry ^a   Laframboise, Stephane ^a   Ferguson, Sarah ^a   Dodge, Jason ^a   Bernardini, Marcus ^a   Murphy, Joan ^a   Segev, Yakir ^a,b   Sun, Ping ^b   Narod, Steven A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Intraperitoneal chemotherapy; Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEOADJUVANT CHEMOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; COMPARATIVE STUDY; GYNECOLOGIC SURGERY; INTRAPERITONEAL CHEMOTHERAPY; METHODOLOGY; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; POSTOPERATIVE PERIOD;

INTRAPERITONEAL CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; OVARIAN CANCER;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; POSTOPERATIVE PERIOD; SURVIVAL RATE;

EID: 84908319713     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.004     Document Type: Article

References (11)

1. Aletti, G.D., Dowdy, S.C., Gostout, B.S., Jones, M.B., Stanhope, C.R., Wilson, T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:1 (Jan 2006), 77–85.
2. Eisenkop, S.M., Spirtos, N.M., Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival?. Gynecol Oncol 82:3 (Sep 2001), 435–441.
3. Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Burger, R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:17 (Sep 2003), 3194–3200.
4. Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q., Baergen, R., Lele, S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. Gynecologic Oncology Group. N Engl J Med 354:1 (Jan 2006), 34–43.
5. Walker, J.L., Armstrong, D.K., Huang, H.Q., Fowler, J., Webster, K., Burger, R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100:1 (Jan 2006), 27–32.
6. Vergote, I., Tropé C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:10 (Sep 2010), 943–953.
7. Vergote, I., Leunen, K., Amant, F., Primary surgery or neoadjuvant therapy in primary ovarian cancer. What is the value of comparing apples with oranges?. Gynecol Oncol 124:1 (Jan 2012), 1–2.
8. Bristow, R.E., Chi, D.S., Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:3 (Dec 2006), 1070–1076.
9. Chi, D.S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitao, M.M., et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124:1 (Jan 2012), 10–14.
10. Skipper, H.E., Adjuvant chemotherapy. Cancer 41:3 (Mar 1978), 936–940.
11. McLaughlin, J.R., Rosen, B., Moody, J., Pal, T., Fan, I., Shaw, P.A., Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 105:2 (Jan 2013), 141–148.